Clinical Trials Browser

Phase 2 × Interventional × ARX788 × Clear all

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06224673 2026-05-01

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT04829604 2026-03-09

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06663748 2024-10-29

ARX788 in HER2-positive Metastatic Breast Cancer Patients

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06578286 2024-08-29

ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

Phase 2 Not yet recruiting

Breast Neoplasms

NCT04983121 2022-09-13

Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients

Phase 2 Recruiting

Breast Neoplasms

NCT05041972 2022-09-13

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Phase 2 Withdrawn

BreastGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05018702 2022-06-01

ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases

Phase 2 Unknown

Brain Neoplasms, Breast Neoplasms

NCT05018676 2022-04-25

ARX788 in Breast Cancer With Low Expression of HER2

Phase 2 Unknown

Breast Neoplasms